FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38105 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 ETHZilla Corporation (Exact name of registrant as specified in its charter) | Delaware | 90-1890354 | | --- | --- | | ( ...

Financial Performance - ETHZilla generated $4.1 million in revenue during the first six weeks of operation as ETHZilla, with a gross profit of $4.1 million[1][5] - The company reported a net loss from continuing operations of $208.7 million, primarily due to one-time non-cash items[7] - Adjusted EBITDA for the quarter was $8.5 million, indicating positive operational performance despite the net loss[7] - For the nine months ended September 30, 2025, the net loss was $212,008, compared to a net loss of $1,659 for the same period in 2024[16] - EBITDA for the nine months ended September 30, 2025, was $(211,688), while Adjusted EBITDA was $5,810, compared to $(1,630) and $(1,355) respectively for the same period in 2024[17] - The company reported net cash used in operating activities of $(18,419) for the nine months ended September 30, 2025, compared to $(546) for the same period in 2024[16] - Cash flows from investing activities totaled $(252,370) for the nine months ended September 30, 2025, with purchases of digital assets amounting to $(243,480)[16] - Net cash provided by financing activities was $825,123 for the nine months ended September 30, 2025, compared to $(1,010) for the same period in 2024[16] - The company ended the period with cash, cash equivalents, and restricted cash totaling $558,901, up from $150 at the end of the same period in 2024[16] - Stock-based compensation expense for the nine months ended September 30, 2025, was $208,923, compared to $275 for the same period in 2024[17] Capital and Investments - The company secured approximately $931 million in institutional capital through various financings, including a $425 million PIPE and a $360 million convertible note[3] - A strategic partnership with Liquidity.io was established, including a $15 million investment and a 15% equity stake in Satschel, Inc., aimed at tokenizing high-value real-world assets[3] - A share repurchase program was initiated, with 2,099,472 shares repurchased for $46.3 million under a $250 million authorization[6] - The company plans to continue opportunistic share repurchases and expects revenue-generating real-world assets on-chain in the coming weeks[6] - The company plans to continue purchasing ETH over time as part of its digital asset treasury strategy[25] Asset Management - ETHZilla's ETH holdings amounted to 102,273 ETH, valued at $424 million, with 70% of ETH deployed in staking protocols[8] - The company anticipates positive adjusted EBITDA in the fourth quarter and expects L2 protocol yield to range between 3.5% and 4.5%[6] - ETHZilla aims to lead the tokenization of global assets, positioning itself as a first mover in the multi-trillion-dollar tokenized asset economy[2] Risks and Projections - The financial projections are based on numerous assumptions and are subject to significant uncertainties, which may materially impact actual results[23] - Forward-looking statements indicate potential risks including fluctuations in the market price of ETH and regulatory changes affecting the cryptocurrency market[25]

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38105 180 LIFE SCIENCES CORP (Exact name of registrant as specified in its charter) | Delaware | 90-1890354 | | --- | --- | | (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38105 180 LIFE SCIENCES CORP (Exact name of registrant as specified in its charter) | Delaware | 90-1890354 | | --- | --- | | (St ...